Findings from a phase I/II study suggest that nivolumab is safe and effective in advanced liver cancer. Based on the results of the phase I part of the study, eight (19%) of the 42 evaluable patients responded to the anti-PD-1 antibody with tumour reduction beyond 30%. More importantly, the responses have been durable and surpassed 12 months in four patients. The overall survival rate at 12 months was 62%.
Presented by Anthony B. El-Khoueiry, MD, University of Southern California Norris, Comprehensive Cancer Center, Los Angeles, CA at ASCO 2015, Chicago, IL
